Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
Company Description (as filed with the SEC)
EPIRUS is building a global biosimilar enterprise to improve patient access to important medicines. The company's strategy for commercial success relies on targeted approaches for diverse global markets. For emerging markets with accessible regulatory frameworks for biosimilars, EPIRUS develops partnerships with local companies to accelerate regulatory approval and commercialize its products. For high-growth global markets where local manufacturing confers strategic and operational advantages, EPIRUS intends to use its SCALE platform to deliver an "In Market, For Market" manufacturing solution with local partners. For large markets with an established biosimilar regulatory framework, such as Europe, EPIRUS plans to commercialize its products using a combination of direct sales and local distributors. EPIRUS' lead product is BOW015, a biosimilar version of Remicade (infliximab), which is used for the treatment of various inflammatory diseases. ... More ...
Where does EPRS fit in the risk graph?
|Annual EPS Est:||$-7.95|
|Quarterly EPS Est:||-0.46|